Trevena

$2.07
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.48%) Today
-$0.01 (-0.48%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Trevena and other stocks, options, and ETFs commission-free!

About TRVN

Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA. The listed name for TRVN is Trevena, Inc. Common Stock.

CEO
Carrie L. Bourdow
Employees
24
Headquarters
Chesterbrook, Pennsylvania
Founded
2007
Market Cap
322.86M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
3.34M
High Today
$2.14
Low Today
$1.87
Open Price
$2.11
Volume
5.82M
52 Week High
$3.68
52 Week Low
$0.46

TRVN Earnings

-$0.09
-$0.06
-$0.03
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, Pre-Market

You May Also Like

NEE-N
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure